Lutetium-177 (Lu-177) Market is Segmented by Type (Non-carrier-added, Carrier-added), by Application (Nuclear Therapy, Others). The Lutetium-177 market is poised for significant expansion as demand ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...

Discover comprehensive details about Lutetium Lu 177 Dotatate, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

Review the side-effects of Lutetium Lu 177 Dotatate as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

Lantheus licensed exclusive worldwide rights (excluding certain territories) to PNT2003 from POINT Biopharma Global, Inc. in December 2022. To read the press release announcing that licensing ...

The FDA has given tentative approval to the abbreviated new drug application (ANDA) for PNT2003, a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) indicated for treatment of ...

Urology consultation: MRI of a male pelvis showing the bladder and the prostate. Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and ...

The appraisal committee considered evidence from a number of sources. See the committee papers for full details of the evidence. The committee understood that neuroendocrine tumours (NETs) can affect ...

Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the successful completion of a new production ...

Lutetium-149 undergoes a rare type of radioactive decay. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Breaking space news, the latest updates ...